Ogivri
Payments companies reported to CMS as associated with Ogivri. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ogivri, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ogivri
These are the largest totals companies reported as associated with Ogivri. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sara Horst | Nashville, TN | Gastroenterology (Internal Medicine) | $2,593.00 |
| Amir Mehdi Ansari | Baltimore, MD | Internal Medicine | $448.34 |
| Onyemaechi Okolo-Taku | Gilbert, AZ | Hematology & Oncology | $279.57 |
| Mohsen Arani | The Woodlands, TX | Hematology & Oncology | $255.62 |
| Yin Wu | Baltimore, MD | Hematology & Oncology | $60.01 |
| Naixi Chen | Renton, WA | Hematology & Oncology | $59.94 |
| Hillary Hahm | Marietta, GA | Hematology & Oncology | $58.36 |
| Omer Ilyas | Clovis, CA | Hematology & Oncology | $54.93 |
| Stanley Nabrinsky | Elgin, IL | Hematology & Oncology | $51.38 |
| David Tamura | Honolulu, HI | Hematology & Oncology | $50.14 |
Prescribed Ogivri?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.